Stifel analyst Mathew Blackman noted that Tandem Diabetes' CFO commented at an investor conference this morning that the company expects Q4 revenues "fully within the company's previously provided guidance range," which would imply full-year sales of $358M-$365M. Such an "in-line" Q4 would compare to recent quarterly revenue upside ranging from 6% to 35%, though this should not come as a significant surprise given slower than expected Control-IQ FDA approval, added Blackman. A lack of meaningful upside in Q4, and his suspicion that the 2020 outlook could prove similarly "in-line," at least initially, lead Blackman to think Tandem shares will remain range-bound and keep a Hold rating on the stock.